This week in Drug Discovery (6 – 10 April)
News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW.
This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Lilly has made the headlines for both an approved drug and a drug collaboration.
The top stories:
Research uncovers previously unknown recessive condition
Researchers have discovered how genetic mutations can cause neuro-developmental disorders, including a previously unknown recessive condition.
Trial to test CAR T-cell therapies as childhood cancer cures
A first-of-its-kind trial has launched to explore whether personalised CAR T-cell immunotherapy could treat childhood cancers.
FDA approves Lilly’s GLP-1 pill for weight loss
The US Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems.
AC Immune and Lilly reach agreement on drug collaboration
Biopharmaceutical company AC Immune has reached an amended agreement with Eli Lilly for the development of an Alzheimer’s treatment.
Read more…
Alzheon doses first patient with novel Alzheimer’s drug
The first patient has been dosed in Alzheon’s Phase I trial of its Alzheimer’s drug.
Read more…